HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response.

AbstractBackground:
As the indication for immunotherapy is rapidly expanding, it is crucial to accurately identify patients who are likely to respond. Infiltration of B cells into many tumor types correlates with a good response to immune checkpoint inhibitor (ICI) therapy. However, B cells' roles in the anti-tumor response are far from clear.
Methods:
Based on single-cell transcriptomic data for ICI-treated patients, we identified a B-cell cluster [BIR (ICI-Responsive B) cells] and described the phenotype, cell-cell communication, biological processes, gene signature, and prognosis value of BIR cells through bioinformatic analysis, tissue immunofluorescence, and animal experiments. Surgery samples from 12 non-small cell lung carcinoma (NSCLC) patients with adjuvant checkpoint blockade were evaluated as external validation.
Results:
BIR cells were identified as a subset of CD20+CD22+ADAM28+ B cells with a memory phenotype. Bioinformatic analysis revealed that BIR cells had enhanced cell viability and epigenetic regulation, and that ALOX5AP, MIF, and PTPRC/CD45 expressed by myeloid cells may be critical coordinators of diverse biological processes of BIR cells. Immunofluorescence confirmed the presence of BIR cells in tertiary lymphoid structures (TLSs) in skin SCC, RCC, CRC, and breast cancer. BIR-associated gene signatures correlate with positive outcomes in patients with melanoma, glioblastoma, NSCLC, HNSCC, or RCC treated with ICI therapy, and BIR-cell density predicted NSCLC patients' response to checkpoint immunotherapy. In line with this, melanoma-bearing mice depleted of BIR cells were resistant to ICIs.
Conclusions:
CD20+CD22+ADAM28+ BIR cells were present in cancer-associated TLS and promoted the response to ICI therapy.
AuthorsZhenghao Wu, Junjie Zhou, Yunxiao Xiao, Jie Ming, Jing Zhou, Fang Dong, Xiaoqi Zhou, Zhuoshuo Xu, Xiangwang Zhao, Ping Lei, Tao Huang
JournalFrontiers in immunology (Front Immunol) Vol. 13 Pg. 865596 ( 2022) ISSN: 1664-3224 [Electronic] Switzerland
PMID35634306 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Wu, Zhou, Xiao, Ming, Zhou, Dong, Zhou, Xu, Zhao, Lei and Huang.
Chemical References
  • Antigens, CD20
  • CD22 protein, human
  • Sialic Acid Binding Ig-like Lectin 2
  • ADAM Proteins
  • ADAM28 protein, human
Topics
  • ADAM Proteins
  • Animals
  • Antigens, CD20 (genetics)
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell (etiology)
  • Cell Count
  • Epigenesis, Genetic
  • Humans
  • Immunotherapy
  • Kidney Neoplasms (etiology)
  • Lung Neoplasms
  • Melanoma
  • Mice
  • Sialic Acid Binding Ig-like Lectin 2
  • Tertiary Lymphoid Structures

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: